Pipeline

Directed To Deliver

Voyager is advancing early-stage programs powered by proprietary, next-generation AAV capsids to deliver innovative gene therapies using various payloads. The pipeline supports the Company’s strategic vision for developing best-in-class treatments by focusing on validated targets, following efficient pathways to preclinical and clinical proof of concept, and seeking opportunities to provide meaningful therapeutic benefit to patients in areas of significant unmet need.

Program (Mechanism)

Ownership

Early Research

Late Research

IND-Enabling

Alzheimer’s disease
Passive Tau Antibody
Wholly-Owned
Late Research

Voyager is developing novel and complementary approaches to disrupt the progression of tau pathology to address tauopathies including Alzheimer’s disease. We believe our passive-immunity anti-tau antibodies are highly differentiated from competitive approaches by offering improved targeting of specific regions of the tau protein that could offer an improved clinical profile compared to first generation approaches.

ALS
SOD1 Gene Therapy (Gene Silencing)
Wholly-Owned
Late Research

Superoxide dismutase 1 (SOD1) mutations cause toxic gain of function in forms of familial amyotrophic lateral sclerosis (ALS), a devastating neurodegenerative disease with minimally effective treatments. Voyager’s SOD1 knockdown program aims to address ALS caused by SOD1 mutations by combining a highly potent siRNA construct with a CNS-tropic, BBB penetrant capsid identified from Voyager’s TRACER platform, allowing for intravenous AAV dosing to enable broad CNS knockdown of SOD1 and slow of the decline of functional ability.

Early Research Programs*
Wholly-Owned
Early Research
Friedreich’s Ataxia
FXN Gene Therapy (Gene Replacement)
Neurocrine Collaboration**
Late Research
Parkinson’s / Others
GBA1 Gene Therapy (Gene Replacement)
Neurocrine Collaboration***
Late Research
Undisclosed Diseases
Five Gene Therapy Programs
Neurocrine Collaboration
Rare Neurological Disease
Gene Therapy
Pfizer License
CNS Diseases
Three Gene Therapy Programs
Novartis Option

*Allele-specific mHtt + MSH3 gene silencing for HD; vHER2 antibody for brain metastases.

**After the Phase 1 readout, Voyager has the option to either: (1) co-develop and co-commercialize with Neurocrine in the U.S. under a 60/40 cost- and profit-sharing arrangement (Neurocrine/Voyager), or (2) grant Neurocrine Biosciences full U.S. commercial rights in exchange for milestone payments and royalties based on U.S. sales.

*** After the Phase 1 readout, Voyager has the option to either: (1) co-develop and co-commercialize with Neurocrine Biosciences in the U.S. under a 50/50 cost- and profit-sharing arrangement, or (2) grant Neurocrine Biosciences full U.S. commercial rights in exchange for milestone payments and royalties based on U.S. sales.

Patient Resources

Here we have gathered resources for patients and caregivers looking to better understand the diseases we seek to treat. If you are a patient or caregiver, please feel free to contact Voyager with questions: info@voyagertherapeutics.com

Huntington’s Disease

Amyotrophic Lateral Sclerosis

Spinal Muscular Atrophy

Parkinson’s Disease

Gaucher

Additional Resources

Contact Us

Voyager Therapeutics
64 Sidney St. | Cambridge, MA 02139
857-259-5340